Kyverna Therapeutics IncNASDAQ:KYTX
- LAST PRICE4.2565
- TODAY'S CHANGE (%)0.2665 (6.6792%)
- Bid / Lots4.2100/ 7
- Ask / Lots4.2600/ 2
- Open / Previous Close4.0000 / 3.9900
- Day Range
- 52 Week Range
- Volume125,876
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KYTX |
|---|---|---|
| 09:32 ET | 1094 | 4 |
| 09:33 ET | 3147 | 3.98 |
| 09:37 ET | 180 | 3.945 |
| 09:39 ET | 829 | 3.9652 |
| 09:42 ET | 851 | 3.98 |
| 09:44 ET | 100 | 4.04 |
| 09:46 ET | 1794 | 4.01 |
| 09:48 ET | 962 | 4.045 |
| 09:50 ET | 132 | 4.0451 |
| 10:02 ET | 300 | 4.05 |
| 10:04 ET | 210 | 4.1 |
| 10:06 ET | 450 | 4.1 |
| 10:08 ET | 1221 | 4.14 |
| 10:09 ET | 200 | 4.12 |
| 10:11 ET | 1404 | 4.145 |
| 10:13 ET | 1018 | 4.12 |
| 10:15 ET | 100 | 4.105 |
| 10:18 ET | 100 | 4.11 |
| 10:22 ET | 200 | 4.08 |
| 10:27 ET | 2100 | 4.08 |
| 10:31 ET | 206 | 4.06 |
| 10:33 ET | 605 | 4.059 |
| 10:38 ET | 100 | 4.06 |
| 10:47 ET | 100 | 4.07 |
| 10:56 ET | 21647 | 4.26 |
| 10:58 ET | 21314 | 4.15 |
| 11:00 ET | 21694 | 4.195 |
| 11:12 ET | 1195 | 4.21 |
| 11:16 ET | 200 | 4.235 |
| 11:18 ET | 100 | 4.235 |
| 11:20 ET | 100 | 4.235 |
| 11:21 ET | 200 | 4.25 |
| 11:23 ET | 2958 | 4.3 |
| 11:25 ET | 700 | 4.32 |
| 11:27 ET | 1300 | 4.3101 |
| 11:32 ET | 2371 | 4.3 |
| 11:34 ET | 3706 | 4.31 |
| 11:36 ET | 2871 | 4.245 |
| 11:38 ET | 10534 | 4.3 |
| 11:39 ET | 144 | 4.305 |
| 11:43 ET | 200 | 4.29 |
| 11:50 ET | 499 | 4.2524 |
| 11:52 ET | 100 | 4.25 |
| 11:54 ET | 646 | 4.239 |
| 11:56 ET | 250 | 4.2565 |
Nov 20, 2024
DJ Kyverna Therapeutics Is Maintained at Neutral by HC Wainwright & Co., from 8:10AM ET on Wednesday Nov 20, 2024 by Dow Jones
8:10AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 15, 2024
DJ Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo, from 2:22PM ET on Friday Nov 15, 2024 by Dow Jones
2:22PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
Nov 13, 2024
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results, from 4:14PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:14PM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results, from 4:14PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:14PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kyverna Therapeutics Inc | 172.2M | -1.7x | --- |
Nkarta Inc | 172.2M | -1.3x | --- |
Inozyme Pharma Inc | 172.8M | -1.7x | --- |
Tenaya Therapeutics Inc | 171.1M | -1.6x | --- |
Greenwich Lifesciences Inc | 170.5M | -16.9x | --- |
Immutep Ltd | 269.6M | -8.3x | --- |
Company Information
Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. It is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
Contact Information
- Headquarters
- 5980 Horton Street, Suite 550EMERYVILLE, CA, United States 94608
- Phone
- 510-626-8331
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Ian Clark
- Chief Executive Officer, Director
- Warner Biddle
- Chief Financial Officer
- Ryan Jones
- President, Research and Development
- Dominic Borie
- Chief Technology Officer
- Karen Walker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $172.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.50 |
Book Value | $1.14 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
